Additional information
| Trade Name | PERJETA |
|---|---|
| Generic Name | Pertuzumab |
| Manufacturer | Roche Products India Pvt Ltd |
| Drug Type | Oncology |
| Indication | Breast Cancer |
| Doasage Form | Injectible |
| Packaging | 1 x 14ml /420mg |
PERJETA (Pertuzumab)-420mg
Perjeta (Pertuzumab) is an “antineoplastic agent and a monoclonal antibody” drug. The monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death. Perjeta™ binds to a different area of the HER2 protein than trastuzumab so that when pertuzumab is combined with trastuzumab, a more complete blockage of HER2 signaling occurs.
It is used in combination with Herceptin (Trastuzumab), another targeted therapy medicine, for the treatment of patients with HER2-positive metastatic breast cancer that hasn’t been treated with either Herceptin or chemotherapy yet.
